Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Tricia Santos Cavaiola, Jeremy Pettus Division of Endocrinology and Metabolism, University of California San Diego, San Diego, CA, USA Abstract: As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diab...
Guardado en:
Autores principales: | Santos Cavaiola T, Pettus J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/22fde3a5635941f3ab60581c846e8217 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019) -
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Fan Yang, et al.
Publicado: (2020) -
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
por: Hirai K, et al.
Publicado: (2020) -
Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
por: Ito H, et al.
Publicado: (2019) -
DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
por: Marina V. Shestakova
Publicado: (2019)